Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 9,500 shares, a drop of 25.8% from the May 31st total of 12,800 shares. Currently, 0.4% of the company’s stock are sold short. Based on an average trading volume of 96,100 shares, the days-to-cover ratio is presently 0.1 days.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock traded down $0.06 during trading on Friday, reaching $6.99. The company’s stock had a trading volume of 14,534 shares, compared to its average volume of 42,840. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 1-year low of $1.86 and a 1-year high of $10.70. The company has a 50-day simple moving average of $7.93 and a two-hundred day simple moving average of $5.39.

Benitec Biopharma (NASDAQ:BNTC) last posted its quarterly earnings data on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter. On average, sell-side analysts predict that Benitec Biopharma will post -7.67 EPS for the current fiscal year.

Institutional Trading of Benitec Biopharma

An institutional investor recently bought a new position in Benitec Biopharma stock. Adage Capital Partners GP L.L.C. acquired a new position in Benitec Biopharma Inc. (NASDAQ:BNTC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 189,188 shares of the biotechnology company’s stock, valued at approximately $572,000. Adage Capital Partners GP L.L.C. owned approximately 7.42% of Benitec Biopharma at the end of the most recent reporting period. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BNTC has been the topic of a number of analyst reports. Piper Sandler initiated coverage on Benitec Biopharma in a report on Thursday, June 13th. They issued an “overweight” rating and a $30.00 price target on the stock. JMP Securities lifted their price target on Benitec Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a report on Monday, April 22nd.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.